Related Experiment Video

Updated: Jun 4, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.3K

Hypomagnesemia is a Risk Factor for Acute Kidney Injury in Patients Admitted With ST-Segment Elevation Myocardial

Youkai Jin1, Qingcheng Lin2, Dingzhou Wang3

  • 1Department of Cardiology, The People's Hospital of Yuhuan, Taizhou, China.

Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation
|December 26, 2024
PubMed

Insights

Hypomagnesemia, or low serum magnesium, is a significant risk factor for acute kidney injury (AKI) in ST-segment elevation myocardial infarction (STEMI) patients. Early identification and management of low magnesium may help reduce AKI incidence.

Area of Science:

  • Cardiology
  • Nephrology
  • Clinical Biochemistry

Background:

  • Acute kidney injury (AKI) is a common complication in ST-segment elevation myocardial infarction (STEMI) patients, associated with poor cardiovascular outcomes.
  • Hypomagnesemia has been linked to increased AKI risk in various populations, but its specific role in STEMI patients requires further investigation.

Purpose of the Study:

  • To examine the association between admission serum magnesium levels and the incidence of AKI in patients hospitalized with STEMI.

Main Methods:

  • A retrospective study included 1,219 STEMI patients, categorized into hypomagnesemia (<0.75 mmol/L) and nonhypomagnesemia groups.
  • AKI incidence during hospitalization was the primary outcome.
  • Univariate and multivariate logistic regression analyses were employed to assess the relationship between serum magnesium and AKI.

Main Results:

  • Of the 1,219 patients, 13.4% had hypomagnesemia, and 21.0% developed AKI.
  • AKI incidence was substantially higher in the hypomagnesemia group (31.9%) compared to the nonhypomagnesemia group (19.3%; P < .001).
  • Multivariate analysis confirmed hypomagnesemia as an independent risk factor for AKI (OR: 2.41, 95% CI: 1.61-3.62; P < .001).

Conclusions:

  • Admission hypomagnesemia is an independent predictor of AKI in STEMI patients.
  • Interventions aimed at correcting serum magnesium levels could be a potential strategy to reduce AKI risk in this patient cohort.
Abstract

Keywords:
ST segment elevation myocardial infarctionacute kidney injuryhypomagnesemiamagnesiumrisk factors

More Related Videos

Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury07:03

Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury

Published on: February 15, 2022

1.4K
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research03:13

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research

Published on: November 3, 2023

2.1K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
100
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
448
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
335
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K